Scholarlink

Background <p>Acute myeloid leukemia with erythroid and megakaryocytic differentiation (AML-EMD) is a rare and aggressive presentation of AML characterized by overlapping morphologic, immunophenotypic, and genetic features of erythroid and megakaryocytic lineages. The classification, pathogenesis, and clinical behavior of this entity remain poorly defined.</p> Methods <p>We report a series of three patients in conjunction with a systematic review of reported cases in published literature with AML-EMD.</p> Results <p>Cytogenetic and molecular studies revealed frequent abnormalities including complex karyotypes, <i>TP53</i> mutations, and <i>JAK1/2</i> mutations. Clinically, patients demonstrated a poor-risk profile.</p> Conclusions <p>Collective phenotypic and genetic features suggest that AML-EMD represents a high-risk subgroup of either <i>TP53</i>-mutated AML or AML with myelodysplasia-related genetics, likely reflecting leukemic transformation from multipotent progenitors retaining erythro-megakaryocytic potential. Despite shared biologic features, current classification systems for AML-EMD are diagnostically incongruent. Recognition of this entity will allow for consistent subclassification, prognostication, and future studies aimed at defining its molecular underpinnings and therapeutic vulnerabilities.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Acute myeloid leukemia with bipotential erythroid and megakaryocytic differentiation: a case series and literature review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月18日

查看全文
  • Li-Wei Liu,
  • Shanelle J. De Lancy,
  • Stephanie N. Hurwitz

摘要

Background

Acute myeloid leukemia with erythroid and megakaryocytic differentiation (AML-EMD) is a rare and aggressive presentation of AML characterized by overlapping morphologic, immunophenotypic, and genetic features of erythroid and megakaryocytic lineages. The classification, pathogenesis, and clinical behavior of this entity remain poorly defined.

Methods

We report a series of three patients in conjunction with a systematic review of reported cases in published literature with AML-EMD.

Results

Cytogenetic and molecular studies revealed frequent abnormalities including complex karyotypes, TP53 mutations, and JAK1/2 mutations. Clinically, patients demonstrated a poor-risk profile.

Conclusions

Collective phenotypic and genetic features suggest that AML-EMD represents a high-risk subgroup of either TP53-mutated AML or AML with myelodysplasia-related genetics, likely reflecting leukemic transformation from multipotent progenitors retaining erythro-megakaryocytic potential. Despite shared biologic features, current classification systems for AML-EMD are diagnostically incongruent. Recognition of this entity will allow for consistent subclassification, prognostication, and future studies aimed at defining its molecular underpinnings and therapeutic vulnerabilities.